ATAI Life Sciences NV

ATAI maintains its Stage 2 uptrend, but the active Bullish Exhaustion inflection pattern and recent pullback from highs signal waning upside momentum. Under a Speculative strategy, bullish engagement should be deferred to pullbacks into the rising 9/20 EMA support area for better asymmetry.

• ↑$430.3M cash & equivalents funds operations through 2023
• ↑11 clinical programs targeting mental health disorders
• ↓Q2 revenue $1.7M, down 142.8% YoY, highlighting weak top line